Identification of a clinical signature predictive of differentiation fate of human bone marrow stromal cells

Justyna Magdalena Kowal¹,²*, Sören Möller³, Dalia Ali¹,², Florence Figeac¹,², Torben Barington⁴,⁵, Hagen Schmal⁶,⁷ and Moustapha Kassem¹,²,⁸

Abstract

Background: Transplantation of human bone marrow stromal cells (hBMSCs) is a promising therapy for bone regeneration due to their ability to differentiate into bone forming osteoblastic cells. However, transplanted hBMSCs exhibit variable capacity for bone formation resulting in inconsistent clinical outcome. The aim of the study was to identify a set of donor- and cell-related characteristics that detect hBMSCs with optimal osteoblastic differentiation capacity.

Methods: We collected hBMSCs from 58 patients undergoing surgery for bone fracture. Clinical profile of the donors and in vitro characteristics of cultured hBMSCs were included in uni- and multivariable analysis to determine their predictive value for osteoblastic versus adipocytic differentiation capacity assessed by quantification of mineralized matrix and mature adipocyte formation, respectively.

Results: We identified a signature that explained > 50% of variation in osteoblastic differentiation outcome which included the following positive predictors: donor sex (male), absence of osteoporosis diagnosis, intake of vitamin D supplements, higher fraction of CD146+, and alkaline phosphate (ALP+) cells. With the exception of vitamin D and ALP+ cells, these variables were also negative predictors of adipocytic differentiation.

Conclusions: Using a combination of clinical and cellular criteria, it is possible to predict differentiation outcome of hBMSCs. This signature may be helpful in selecting donor cells in clinical trials of bone regeneration.

Keywords: Human bone marrow stromal stem cells, Osteoblastic and adipocytic differentiation, Cell phenotype, Donor characteristics, CD markers

Background

The clinical efficacy of transplanted human bone marrow stromal cells (hBMSCs) is being tested in an increasing number of clinical trials aiming at enhancing tissue regeneration following injury [1–3]. hBMSCs are easy to isolate from clinical samples and can differentiate into several cell lineages including bone-forming osteoblastic cells which is clinically favorable outcome for bone regeneration [4, 5]. In addition to the differentiation potency, the cells may also be involved in a biological process that supports immunomodulation and tissue regeneration, by secreting paracrine factors [6–8]. Thus, hBMSC transplantation is a promising therapy for bone regeneration for a number of pathologies including non-union and delayed fracture healing or in combination with biomaterials for repairing large bone defects [9–13]. hBMSCs are acknowledged by the Food and
Drug Administration Agency (FDA) as suitable adult stem cells for human clinical trials of bone regeneration, as hBMSCs meet the recent recommendations regarding the use of human cell-based products [14].

While the safety of hBMSC transplantation is acceptable [15, 16], the clinical efficacy with respect to bone regeneration varies among trials [3, 13, 17]. A possible explanation is the functional heterogeneity of the transplanted cells and the lack of a set of standardized in vitro criteria for selecting the most appropriate hBMSCs for treatment [3]. Cellular heterogeneity of in vitro cultured hBMSCs are caused by intrinsic factors related to stem cells, i.e., differences in numbers (indicated by colony-forming efficiency or CD (cluster of differentiation) marker expression), proliferation rate, and factors related to their differentiation capacity, i.e., the ability of the cells to differentiate into bone-forming osteoblastic cells or cells of alternative lineages such as adipocytic cells, which is considered an unwanted outcome when developing therapies for bone regeneration [18–22]. Furthermore, cultured hBMSCs may exhibit variations in their biological characteristics caused by extrinsic factors, i.e., donor age, sex, or the presence of metabolic bone diseases [23–25]. Thus, the clinical use of hBMSCs requires determining the relative contribution of donor-related phenotype and intrinsic cellular characteristics, on osteoblast differentiation outcome, with the aim of selecting the most optimal hBMSC product for clinical applications.

To address these points, we conducted a prospective study, where we obtained bone marrow samples from a clinical cohort undergoing surgery for bone fracture. We determined the biological characteristics of the hBMSCs and correlated these parameters with the clinical phenotype of each individual patient including health profile and lifestyle factors. Using univariable and multivariable analysis, we identified a set of variables predictive for the ability of the cultured hBMSCs to differentiate into bone-forming osteoblastic cells.

**Methods**

**Donors and materials**

The bone marrow was aspirated from the lower extremities of 58 adult donors undergoing surgery at the Department of Orthopedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark. Due to the lack of preliminary data to calculate the sample size and to the exploratory character of the study with unknown variables, we collected the highest possible number of specimens for a duration of 1 year 2016/2017. Collected samples were categorized as “waste material” and the procedure did not pose any additional risk for the patients. All subjects received oral and written information and signed a consent form. Information regarding the health status of each donor was obtained from the patient journal provided by the Danish Healthcare System and during the interview with the medical professional. The project was approved by the Scientific Ethical Committee of the region of Southern Denmark (project ID: S-20160084). Parts of the data from the manuscript have been correlated with cell morphology data in a separate study published by our group [22].

**Cell isolation and culture**

Bone marrow aspirates (5–10 ml) were collected into ethylenediaminetetraacetic acid (EDTA)-coated tubes. hBMSCs were isolated from the mononuclear cell fraction following gradient centrifugation on Lymphoprep®, followed by plastic adherence [25]. The cells were cultured in minimum essential medium (MEM medium) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) at 37°C in humidified 5% CO₂ incubator. After a week, when the first cells adhered to the plastic surfaces, the media were switched to MEM media including 10% FBS, 1% P/S, 1% GlutaMAX, 1% sodium pyruvate, and 1% non-essential amino acids (S-MEM growing medium). The same batch of FBS was used throughout the study. At 80% confluence, the cells were trypsinized and used for subsequent analysis.

**Colony-forming unit-fibroblast (CFU-f) assay**

CFU-f assay was performed in triplicates. The freshly isolated cells were counted under an optical microscope using a hemocytometer and plated at a density of 1 million cells (passage 0) into each of three 22.1cm² Petri dishes (TPP, 93060) and cultured for 17 days under standard culture conditions. The colonies were visualized by crystal violet staining.

**Cell proliferation**

Cell proliferation capacity was performed in triplicates at the first cell passage. The cells were counted under an optical microscope using a hemocytometer and plated at a density of 1000 cells/well in a 6-well plate (TPP, 92006) in triplicates and cultured under standard conditions. At day 1, 3, 6, 9, 12, and 15, the cells were trypsinized and counted in a hemocytometer, and the proliferation capacity of the cells was measured as the area under the curve (AUC). The population doubling time (PDT) in hours between days 1 and 6 was calculated using the following formula: \(\text{PDT} = \frac{120\text{hours}}{s\log(2)/\log(N_{\text{cells day 6}}/N_{\text{cells day 1}})}\).

**Flow cytometry**

hBMSCs after ex vivo expansion to passage 2 were trypsinized and washed with phosphate-buffered saline (PBS) (without Ca²⁺ and Mg²⁺) containing FBS (2%). The cells were incubated with primary fluorophore-
conjugated antibodies as follows: CD146-PE, CD271-FITC, ALPL-APC, PDGFRα-PE, CD34-PE, PDPN-APC, CD164-PE, CD362-PE, and CXCR4-PE for 25 min at 4°C. After the incubation, cells were analyzed using BD LSR II Flow Cytometer (BD FACSDiva). The data were analyzed with Kaluza Flow Cytometry Analysis Software Version 1.3 (Beckman Coulter).

**In vitro cell differentiation**

**Osteoblastic differentiation**

hBMSCs from passage 1 were seeded (20.000 cells/cm²), and after 24h, the media were replaced with osteoblastic induction media supplemented with: 10% FBS, 1% P/S, 5mM β-glycerophosphate, 10nM dexamethasone, 50μg/ml vitamin C, and 10nM vitamin D₃. The media were changed every 2–3 days. After 14 days, the osteoblastic differentiation was assessed. The osteoblastic differentiation was performed in duplicates.

**Alizarin red staining** For visualization of mineralized matrix formation, alizarin red staining was performed. The cells were washed with PBS and fixed with 70% ice-cold ethanol at −20°C for 1h, washed with H₂O, and incubated with alizarin red (pH=4.2) for 10 min with rotation at room temperature (RT). The stained cells were scanned and the potency of the cells to form mineralized matrix was quantified as the intensity of alizarin red using ImageJ software and expressed in arbitrary units (AU).

**Alkaline phosphatase (ALP) activity** The cells were washed with tris-buffered saline (pH 9), fixed with formaldehyde-ethanol for 30 s at RT, and incubated with p-nitrophenyl phosphate (1mg/ml) in 50mM NaHCO₃ and 1 mM MgCl₂, pH 9.6 at 37°C. After 20 min of incubation, 3M NaOH was added to stop the reaction. Absorbance was measured at 405 nm, and ALP activity values were corrected for a number of hBMSCs in each well. The cell number was determined based on cell viability and determined by incubating the cells with CellTiter-Blue for 1h at 37°C. The fluorescent intensity (560ex/590em) was measured in FLUOstar Omega plate reader. In independent experiments from our laboratory, cell viability measurements showed excellent correlation with cell numbers determined by manual counting of the cells.

**Gene expression of osteoblastic markers using quantitative real-time PCR (qRT-PCR)**

The total RNA was isolated from the cells using TRIzol reagent and following the protocol provided by the manufacturer. The reverse transcription was performed using a High Capacity cDNA Reverse Transcription Kit. Quantitative real-time PCR was performed with an Applied Biosystems 7500 Real-Time PCR System using Fast SYBR Green Master Mix with primers of the following genes: Collagen 1A (COL1A), bone sialoprotein (BSP), and osteocalcin (OCN). The sequences of the primers are included in Supplementary Table 1. Gene expression data were normalized to β-actin housekeeping gene and expressed as delta-delta Ct values.

**Adipocytic differentiation** hBMSCs from passage 1 were seeded (30.000 cells/cm²). At near full confluency, the media was replaced with adipocytic induction media containing Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 1% P/S, 5% horse serum, 1μM rosiglitazone (BRL), 3μg/ml insulin, 100nM dexamethasone, and 225μM 3-isobutyl-1-methylxanthine (IBMX) and changed every 2–3 days. After 14 days, adipocytic differentiation efficiency was determined. The adipocytic differentiation was performed in duplicates.

**Oil Red O staining** The formation of mature adipocytes containing lipid droplets was visualized using Oil Red O staining. The cells were fixed with 4% paraformaldehyde (PFA) for 10min at RT, washed with 3% isopropanol, and incubated with filtered Oil Red O solution (25mg of Oil Red O in 5ml of 100% isopropanol and 3.35 ml H₂O). Photomicrographs of the cells were captured using an Olympus optical microscope (×10 magnification objective) and quantified as the area of lipid droplets (average of 6 images per sample) using ImageJ software and expressed in arbitrary units (AU).

**Reagents**

LymphoprepTM (StemCell Technologies, 1114545), minimum essential media (MEM, Gibco, 31095-029), Dulbecco’s modified Eagle’s medium (DMEM, Gibco, 31966), fetal bovine serum (TherFisher, 10270106, lot: 42F0266K), GlutaMAXTM (Gibco, 35050-038), non-essential amino acids (MEM NEAA, Gibco, 11140-035), Trypsin-EDTA (Invitrogen, 25300062), β-glycerophosphate (Calbiochem, 35675), dexamethasone (Sigma, D4902), vitamin C (L-Ascorbic Acid Phosphate Magnesium Salt n-Hydrate, Wako, 013-12061), vitamin D₃ (1α,25-Dihydroxyvitamin D₃ a kind gift from Leo Pharma), p-nitrophenyl phosphate (Sigma, 71768), Alizarin Red (Sigma, A5533), Oil Red O (Sigma, O0625), horse serum (Sigma, H1270), rosiglitazone (BRL,
Cayman Chemical, 71740), insulin (Sigma, I9278), 3-isobutyl-1-methylxanthine (IBMX, Sigma, I5879), Naphthol AS-TR phosphate disodium salt (Sigma, N6125), Fast Red TR Salt hemi(zinc chloride) salt (Sigma, F8764), anti-CD146 (Beckman Coulter, A07483), anti-CD271 (BioLegend, 345104), anti-ALPL (R&D Systems, FAB1448A), anti-CD164 (Miltenyi Biotec; 130-108-069), anti-PDGFRα (BD Biosciences, 556002), anti-CD34 (BD Biosciences; 555822), anti-PDPN (Miltenyi Biotec; 130-106-955), anti-CXCR4 (R&D Systems, FAB170P), anti-CD362 (Miltenyi Biotec; 130-107-480), CellTiter-Blue cells viability assay reagent (Promega, G8081), TRIzol (Invitrogen, 15596018), High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™, 4368813), and Fast SYBR® Green Master Mix (Applied Biosystems™, 4385614).

Data analysis
Analyses were performed using GraphPad Prism 7.1 and Stata 15.1 software. Data are shown as mean ± SD, unless otherwise stated. Statistical significance was considered when p≤0.05. For age, we divided the individual into young (18–45 years), middle-aged (46–65 years), and elderly (>65 years), based on the epidemiological studies of changes of bone mass with aging. BMI was divided into lean (<25), overweight (25–29.9), and obese (>30), similar to the World Health Organization criteria. The normal distribution of all investigated cell and donor-related variables was tested by performing D’Agostino & Pearson normality test. Correlations between variables were investigated using the Pearson or Spearman two-tailed correlation test (rS, correlation coefficient) depending on normality test results. The differences in the distribution of donor population were analyzed with Fisher’s exact test.

Multivariable analysis We performed analysis for the desired outcome of osteoblastic differentiation based on the alizarin red staining and the undesired outcome of adipocytic differentiation based on the oil red O staining. We applied linear regression with stepwise backward selection collectively on clinical parameters (sex, age, body mass index (BMI), presence of osteoporosis, hypertension, diabetes, intake of vitamin D and calcium supplementation, current cigarette smoking, and alcohol consumption) and in vitro cell characteristics (expression of CD146, ALP, CD271, PDGFRα, CD362, CXCR4, CD14, CD34 markers, cell proliferation, number of ALP+ colonies, total number of colonies, and ALP activity at baseline and after osteogenic induction) with a cut-off for exclusion of p = 0.10 and reporting coefficients with 95% confidence intervals, standardized to 1 SD change in case of numerical predictors, and R² of the resulting regression models. Donors with incomplete information regarding clinical or cellular parameters were excluded from the multivariable analysis. To avoid possible sources of bias in a multivariable model, the data were analyzed by a researcher who was not familiar with the findings of the univariable analysis and did not have an expertise in the cell biology field. This allowed for an objective examination of the predictive value of analyzed variables. For artwork, Servier Medical Art by Servier under a Creative Commons 3.0 license was used.

Results
Clinical characteristics of study participants
The clinical phenotype of the 58 participants of the study is shown in Table 1. The studied cohort included both males and females of a wide range of ages (18–97 years) and BMI (17.5–44). hBMSCs were isolated from bone marrow aspirates collected from the femur, tibia, or pelvis. Table 1 also shows the distribution of the following factors within the group: cigarette smoking, alcohol consumption, intake of vitamin D and calcium supplements, clinical biochemistry data, and the presence of the following diseases: osteoporosis, hypertension, and type 2 diabetes. The database also includes information about fracture age, indicating the time of the bone marrow collection from operated fractures, including acute and non-union fractures. In addition, we classified the participants according to the use of medication into two categories: current regular intake of more or less than 3 drugs that included statins, pantoprazole, paracetamol, morphine, or non-steroidal anti-inflammatory drugs.

Cultured populations fulfilled minimal hBMSC criteria
Individual hBMSC isolates (strains), each derived from one single individual, were characterized in vitro (Table 2). Cultured hBMSCs formed colonies (i.e., CFU-f), and many of these expressed alkaline phosphatase (mean ± SD, 37.5 ± 24.5%). The proliferative potency of the hBMSCs calculated as PDT was 73.3 ± 34 hours for all donors. We used area-under-the-curve (AUC) as a summary variable of cell proliferation for each donor. In preliminary experiments, we examined hBMSC surface markers recommended by the International Society for Cellular Therapy (ISCT, [26]). We tested cells from 15 consecutive donors and found that ≥98% of cell populations demonstrated positive expression of CD44, CD90, CD105, and CD73 and with minimal inter-individual variations [22]. These data confirmed that the cells in our study fulfilled the criteria of hBMSCs. However, these standard CD markers were not suitable as predictive markers due to the absence of inter-individual variations and they were not determined in the remaining cohort.
The aim of the study was to use the differentiation capacity of individual hBMSC strains as a clinically relevant outcome. We therefore quantified the ability of the hBMSCs to differentiate into osteoblastic cells (OB), based on mineralized matrix formation or to differentiate into the alternative undesired outcome; mature adipocytes (AD), based on measuring the area occupied by lipid droplets. As shown in Fig. 1a, we categorized the hBMSC strains (each derived from an individual donor) according to the ability to differentiate into OB or AD, into four groups: good at OB and AD differentiation (OB+AD+), good at OB but poor at AD differentiation (OB+AD−), poor at OB and good at AD differentiation (OB−AD+), poor at differentiation into

### Table 1 Clinical characteristics of the donors

| Variable                                  | Distribution (n of donors) |
|-------------------------------------------|-----------------------------|
| Males/females                             | 26/32                       |
| Age (18–45 years/46–65 years/ >65 years)  | 19/16/25                    |
| BMI (<25/25–29.9/≥30)                     | 24/16/18                    |
| Bone marrow aspiration site (femur/tibia/pelvis) | 25/27/6                    |
| Cigarette smoking (currently smoking/non-smoking) | 21/37                     |
| Alcohol consumption ≥8g/day (yes/no)      | 37/21                       |
| Osteoporosis (yes/no)                     | 22/36                       |
| Diabetes type 2 (yes/no)                  | 10/48                       |
| Hypertension (yes/no)                     | 21/37                       |
| Number of medications (<3/3≤)             | 45/23                       |
| Vitamin D supplementation (yes/no)        | 20/46                       |
| Calcium supplementation (yes/no)          | 20/46                       |

| Variable | Average (range) |
|----------|-----------------|
| Weight (kg) | 79.5 (44–130)  |
| Height (cm)  | 170.4 (152–192) |
| Haemoglobin (mmol/l) | 7.7 (5–9.6)  |
| Leucocytes (cells/µl) | 9.7 (5–17.6) |
| C-reactive protein - CRP (mg/l) | 34.9 (0.6–244) |
| Fracture age (days) | 79 (1–1095) |

### Table 2 In vitro characteristics of hBMSC strains

| Variable                                           | Mean ± SD   | Number of cell strains tested |
|----------------------------------------------------|-------------|------------------------------|
| Number of ALP positive CFU-f colonies per 1 million plated cells | 9 ± 13      | 48                           |
| Number of all CFU-f colonies per 1 million plated cells | 22 ± 24     | 50                           |
| ALP activity (baseline)                             | 0.3 ± 0.36  | 56                           |
| ALP activity (induced)                              | 2.3 ± 2.1   | 58                           |
| CD14+ cells (%)                                     | 6.8 ± 7.4   | 58                           |
| CD34+ cells (%)                                     | 13.2 ± 18   | 58                           |
| CD146+ cells (%)                                    | 61.7 ± 30.3 | 58                           |
| ALP+ cells (%)                                      | 27.1 ± 17.7 | 58                           |
| CD271+ cells (%)                                    | 26 ± 24.8   | 58                           |
| PDGFRα+ cells (%)                                   | 37.6 ± 28.1 | 58                           |
| CD362+ cells (%)                                    | 30.3 ± 32   | 56                           |
| CXCR4+ cells (%)                                    | 12.2 ± 21.2 | 55                           |
| CD164+ cells (%)                                    | 96.4 ± 7.1  | 33                           |
| PDPN+ cells (%)                                     | 11.2 ± 8.7  | 32                           |
Fig. 1 Distribution hBMSC population according to osteoblastic and adipocytic differentiation outcome. Human bone marrow stromal cells (hBMSCs) were obtained from 58 donors undergoing surgery for bone fractures and were induced into osteoblasts (OB) or adipocytes (AD). The differentiation outcome was demonstrated by the ability of the cells to form mineralized matrix stained with Alizarin red (OB) or lipid-filled mature adipocytes stained with Oil red O (AD). The median values of Alizarin red intensity and lipid droplets area were chosen to classify hBMSC differentiation outcome of all donors, into: (I) donors with low osteoblastic and high adipocytic (OB-AD+), (II) donors with high osteoblastic and adipocytic (OB+AD+), (III) donors with high osteoblastic and low adipocytic (OB+AD-), and (IV) donors with low osteoblastic and adipocytic differentiation (OB-AD-). The representative photomicrographs illustrate matrix mineralization and lipid droplet accumulation. The correlation between the osteoblastic and adipogenic differentiation potency of hBMSCs was analyzed using Spearman correlation test. Column graphs illustrate the distribution of donor characteristics with respect to differentiation outcome: b donor sex, c site of bone marrow aspiration, d donor age, and e donor BMI. None of the donor-related factors was significantly linked with OB or AD differentiation (Fisher’s exact test).
OB and AD (OB−AD−). This classification was based on whether the quantitative differentiation outcome was above or below the median value of the whole cohort (Fig. 1a and the representative photomicrographs). Using Fisher’s exact test, we did not detect significant associations between the basic donor characteristics (sex of the donor, bone marrow sampling site, donor age, and BMI) and OB or AD differentiation (Fig. 1b–e).

In addition, we determined gene expression of a number of osteoblast lineage genes: BSP and COL1 (Supplementary Figures 1, 2) at day 14, which is a typical endpoint of OB differentiation. We detected a significant correlation (Supplementary Figure 2) between BSP expression which is a late marker of OB differentiation and alizarin red staining (Supplementary Figure 2A). Also, BSP expression was higher in the cell strains with the highest OB differentiation (Supplementary Figure 1B). For COL1A and OCN expression (both are early markers OB differentiation) [27], the correlation with Alizarin red staining was not significant (Supplementary Figure 2B-C) as well their ability to identify cell strains with the highest OB differentiation outcome (Supplementary Figure 1B-C). When we combined the 3 gene markers (Supplementary Figure 2D), the correlation with Alizarin red staining improved but was not statistically significant.

Univariable correlation between in vitro features and differentiation outcome of hBMSCs
We examined if the standard characteristics of cultured hBMSCs could predict their differentiation outcome. Both OB and AD differentiation were positively correlated with the percentage of ALP+ cells (Fig. 3a, b, \( p = 0.0004 \) and \( p = 0.0007, n = 58 \)). On the other hand, the enzymatic activity of ALP measured at baseline, positively correlated only with OB differentiation (Fig. 3c, \( p = 0.0007, n = 56 \)), and not with AD differentiation (Fig. 3d, \( p = 0.08, n = 56 \)). Similarly, ALP activity measured at day 7 following culturing the cells in OB induction medium had a strong positive correlation with OB differentiation (\( p < 0.0001, n = 58 \)) but not with AD differentiation (Fig. 3e, f).

We did not detect a significant correlation between the proliferative capacity of the cells (Supplementary figure 3A-B), the number of total CFU-f colonies, or ALP+ CFU-f colonies (Supplementary figure 4A-E) and OB or AD differentiation. Similarly, we did not observe any significant correlations when the studied cohort was analyzed according to donor sex (Supplementary Table 4).

Univariable correlations between expression of cell surface marker and differentiation outcome of hBMSCs
The standard CD markers (CD44, CD73, CD90, CD105) recommended by ISCT [26] were homogenously expressed (>98% positive) [22] in all tested cell strains. Regarding the negative CD markers recommended by ISCT, CD45 was homogenously expressed (<95% negative). These markers were therefore not useful in explaining inter-individual variations in OB differentiation outcome. We therefore chose to focus on the negative markers CD14 and CD34 which varied among the samples and a number of novel surface markers of hBMSCs [28–30] that were heterogeneously expressed among different cell strains. As shown in Fig. 4, univariable analysis demonstrated that the number of CD146+ cells positively correlated with the OB differentiation (Fig. 4a, \( p = 0.0003 \)), whereas the number of PDGFRα+ and CD34+ cells exhibited positive correlations with AD differentiation (Fig. 4d, \( p = 0.03, p = 0.0002 \), respectively). We also tested the relationship between the expression of CD271 [31, 32], CD362 (a marker associated with immunomodulation of hBMSCs [33]), CXCR4 (receptor associated with homing properties of hBMSCs [34, 35]), CD164 and podoplanin (PDPN) membrane markers that have recently been reported to define multipotent human skeletal stem cells [36], and hBMSC differentiation outcome. Although, these markers were heterogeneously expressed in hBMSC populations, we did not observe any significant correlations between the number of cells expressing these markers and the differentiation capacity of the cells (Table 2 and Supplementary Figure 5).
Multivariable analysis

We performed multivariable analysis using a stepwise regression model with OB or AD differentiation as the main outcome. As we detected that there was a difference between males and females in our study, we performed a post hoc analysis of age-sex interaction and this analysis demonstrated the absence of significant effects on OB and AD differentiations. These findings indicate that there is no interaction between age and sex of the hBMSC donors in predicting the AD/OB outcome.
and support the findings that the sex effect was not confounded by donor age. To fully investigate the importance of all variables collected in the cohort, we further performed multivariable analysis including all donor- and cell-related variables to identify a group of factors that are predictive for in vitro osteoblast or adipocyte formation.

The list of factors that was selected as highly contributing (significance cut-off \( p < 0.1 \)) to OB or AD differentiation is shown in Table 3. We identified six variables that were predictive for OB differentiation: sex of the donor \( (p = 0.001) \), presence of osteoporosis \( (p = 0.004) \), intake of vitamin D supplements \( (p = 0.003) \), fraction of CD146+ cells \( (p = 0.004) \), fraction of ALP+ cells \( (p = 0.005) \), and CD14+ cells \( (p = 0.089) \).

Employing the same model, seven factors were selected as predictive for AD differentiation outcome. Four of them: sex of the donor \( (p = 0.006) \), presence of osteoporosis \( (p < 0.001) \), number of CD146+ cells \( (p = 0.009) \), and number of ALP+ cells \( (p = 0.02) \) are in common with the findings for OB differentiation but except for the ALP+ expression; these have the opposite effect on adipocyte formation. Three additional variables were predictive for AD differentiation: the number of PDGF Rα+ cells \( (p = 0.016) \), CD362+ cells \( (p = 0.073) \), and alcohol consumption \( (p = 0.095) \). Combined, all predictive

Fig. 3 Correlation of alkaline phosphatase (ALP) with differentiation outcome of hBMSCs. a, b The correlation of percentage of ALP+ cells, c, d ALP activity measured at baseline, e, f ALP activity measured at day 7 of osteoblastic differentiation, with the final osteoblastic and adipocytic differentiation outcome, respectively. Analyzes were performed using Spearman correlation test. Each dot represents the average value of cultured cells from a single donor, \( r_s \) = Spearman’s rank correlation coefficient, and \( n \) = number of tested cell strains, each derived from a single donor.
variables explain more than 50% of the variation observed within the data ($R^2 = 0.552$ for OB differentiation and $R^2 = 0.557$ for AD differentiation).

**Discussion**

In the current study, we demonstrated that by combining key characteristics of donors and of cultured hBMSC strains, we were able to generate a model of collective variables that predicts > 50% of variation in osteoblast and adipocyte differentiation outcome. The model identified the following factors for selecting cells with the enhanced ability for in vitro mineralized matrix formation: male sex, absence of osteoporosis, current intake of vitamin D supplementation, and a higher number of ALP+ and CD146+ in cell cultures.

Both uni- and multivariable analysis revealed that the sex of the donor is a significant predictor for OB differentiation outcome. In contrast to our study, a number of previous reports did not detect a significant impact of donor sex on the number of committed OB or their differentiation outcome [23, 37–40]. For example, we were not able to detect sex differences of cultured hBMSC in one of our previous studies, which only included a cohort of younger donors, aged 20-35 [39]. One could presume that sex differences in the biology of hBMSCs became detectable with aging as we in the current study also included older patients. However, we could not demonstrate any significant interaction between sex and age on predicting OB and AD differentiation potency when applying multivariable analysis. Our data thus
suggest that sex itself is an independent predictor for OB and AD differentiation outcome.

The influence of donor age on the biological properties of the hBMSCs has been previously examined in both animal and human studies [41], and the reported results have not been consistent. Some studies have reported that the hBMSCs obtained from elderly donors exhibit a reduced expression of osteoblastic gene markers, ALP activity, and decreased mineralized matrix formation [42–44], while others reported no age-related effects on the ability of the cells for OB or AD differentiation [23, 45, 46]. In vivo transplantation studies of hBMSCs have demonstrated similar bone-forming capacity regardless of donor age [25, 47, 48]. In vivo transplantation studies of hBMSCs have demonstrated similar bone-forming capacity regardless of donor age [25, 47, 48]. Interestingly, we have previously reported that the effect of donor age on hBMSC biology was only detectable during a long term (>60 days) in vitro culture and was caused by the accumulation of senescent cells [25], suggesting donor age effects may not be detectable in short-term cultures. In addition, the age-related effects were reported mainly on the proliferative capacity of hBMSCs, demonstrating an increased proliferative rate in cells from younger donors with the growing skeleton (<20 years) compared to the cells obtained from elderly donors (>60 years) [41]. Nevertheless, our study corroborates our previous report that hBMSCs obtained from the elderly do maintain their differentiation capacity and thus can be employed in autologous transplantation protocols [39].

In addition to sex and age, we examined the effect of a large number of clinical variables on OB and AD differentiation outcome. We observed that fracture age (<7 days) was positively associated with increased OB differentiation in male donors which may be related to the increased number of osteoblastic stem cells recruited for fracture repair or the release of bone enhancing growth factors [49]. We also observed that increased donor weight, but not BMI, was associated with enhanced AD differentiation outcome in female donors which corroborated our recent study showing that hBMSCs derived from obese healthy donors exhibit enhanced OB and AD differentiation compared to lean [50].

In our study, bone marrow collection site did not influence hBMSC differentiation outcome, which corroborates findings in earlier reports [40, 45]. In the multivariable analysis model, the absence of osteoporosis and intake of vitamin D supplementation were significant predictors for enhanced OB differentiation outcome. Based on a number of previous studies, the effect of osteoporosis, on in vitro mineralized matrix formation has not been consistent with some studies reporting no effect [51] or reduced OB differentiation [52–54] when comparing cultured hBMSCs isolated from osteoporotic donors and controls. We have also previously reported that hBMSC cultures established from osteoporotic patients exhibited similar proliferation and differentiation capacities as age-matched controls [39, 46]. The discrepancy may be explained by the fact that the donor population of the current study exhibited a more severe osteoporotic phenotype and osteoporotic fracture. hBMSCs express the vitamin D receptor, and active metabolites of vitamin D promote OB differentiation by up-regulating osteogenic gene expression, increasing ALP activity and extracellular mineralized matrix deposition

| Variable | N of samples | Standardized regression coefficient (95% CI) | p value |
|----------|-------------|---------------------------------------------|---------|
| Sex | 47 | 20.83 (9.60; 32.05) | 0.001 |
| Osteoporosis | 47 | −27.38 (−45.65; −9.1) | 0.004 |
| Vitamin D supplementation | 47 | 27.08 (9.58; 44.58) | 0.003 |
| CD146+ cells (%) | 47 | 0.28 (0.10; 0.46) | 0.004 |
| ALP+ cells (%) | 47 | 0.51 (0.16; 0.87) | 0.005 |
| CD14+ cells (%) | 47 | −0.69 (−1.49; 0.11) | 0.089 |

**List of donor- and cell-related variables predictive for adipocytic differentiation (R² = 0.557)**

| Variable | N of samples | Standardized regression coefficient (95% CI) | p value |
|----------|-------------|---------------------------------------------|---------|
| Sex | 47 | −7.95 (−16.24; 0.33) | 0.060 |
| Osteoporosis | 47 | 17.36 (8.95; 25.76) | 0.000 |
| Alcohol consumption | 47 | −6.85 (−14.96; 1.26) | 0.095 |
| CD146+ cells (%) | 47 | −0.21 (−0.36; −0.05) | 0.009 |
| ALP+ cells (%) | 47 | 0.31 (0.05; 0.57) | 0.020 |
| PDGFRα+ cells (%) | 47 | 0.22 (0.04; 0.39) | 0.016 |
| CD362+ cells (%) | 47 | −0.17 (−0.36; 0.02) | 0.073 |
in vitro [55–57]. The observed effects of donor/patient vitamin D supplement intake on enhanced ability of cultured hBMSCs for OB differentiation in the current study may be caused by epigenetic changes, which have been observed for other cell types [58] and might include histone deacetylation, which was shown to rejuvenate osteoblastogenesis in hBMSCs from elderly individuals [59]. Thus, vitamin D intake may have positive effects on bone regeneration by targeting hBMSCs.

We further observed a number of cellular characteristics that were predictive for hBMSC differentiation outcome. We found a positive correlation between the number of ALP+ cells and both OB and AD differentiation. ALP is commonly employed marker for early stages of osteoblastic differentiation. However, the expression of ALP has also been detected in AD precursors that reside in the bone marrow [60] and an increased expression of ALP was found in hBMSCs committed to OB and AD fate but not in cells committed to chondrocytes [61]. On the other hand, ALP activity at both at baseline and following OB induction is a good predictor of the ability of cells to become mature bone-forming osteoblastic cells, which corroborate the role of ALP as important factor for bone mineralization [62]. CD146 was another surface marker that showed a positive correlation with OB differentiation outcome. CD146 has been demonstrated to define stem cell populations within hBMSC cultures [29, 32, 63] self-renewing capacity, clonogenicity, and formation of hematopoietic microenvironment in vivo [29, 63].

We also observed that hBMSC strains enriched in cells positive for ALP, PDGFRα, and negative for CD146 and CD362 exhibited enhanced AD differentiation. A similar observation has been reported by Uezumi et al., who demonstrated that human skeletal muscle progenitors enriched in PDGFRα+ cells possess high adipogenic differentiation potential [64]. On the other hand, Samson-raj et al. demonstrated that the high expression of PDGF Rα is associated with high proliferation and increased ability to form bone tissue in vivo [65]. This discrepancy could be explained as PDGFRα is a marker of cells committed to both OB and AD. In our study, we observed a significant positive correlation between CD34 and AD differentiation. CD34 is commonly used as marker for hematopoietic stem cells, but a number of studies have reported that CD34 is also expressed in bone marrow stromal cells among cells with adipogenic [66] or osteoblastic differentiation potential [30].

Our study has some limitations. The hBMSCs were isolated from patients undergoing orthopedic surgery and thus may not represent a random sample of the whole population. Second, due to a limited cell number available from each donor, we examined the differentiation potential into osteoblasts and adipocytes but not to chondrocytes which is a relevant alternative lineage that informs about the “stemness” nature of the cultured cells. Third, we employed a standard 2D-culture system to test the differentiation potential of cultured hBMSCs; however, testing the cells in 3D-culture or testing their ability to form bone organoids may be relevant with respect to clinical applications especially the use of cells in bone tissue engineering as we have reported previously [67]. Finally, the described multivariable model was able to explain only 55% of the observed variations of the osteoblast differentiation outcome, suggesting the presence of smaller effects of multiple additional variables not detected due to the power of the current study and the results need to be validated in independent cohorts.

Conclusions
Our study provides a number of clinically relevant variables that can be tested in prospective clinical trials or in preclinical animal models for bone tissue regeneration. Our findings indicate that the hBMSCs collected from non-osteoporotic male donors with vitamin D supplementation and enriched in fraction of CD146+/ALP+/CD14- cells have enhanced OB differentiation potency; by more than 50%. Moreover, our analysis demonstrates that the hBMSCs collected from osteoporotic females, enriched in subpopulations of ALP+/PDGFRα+ CD146-/CD362- cells, had more than 50% of probability to exhibit an enhanced differentiation potency toward adipocytes formation; considered a non-desired differentiation outcome. Importantly, we think that the variables proposed here are relevant for choosing the most suitable donors to obtain hBMSCs with optimal osteoblast differentiation capacity, potentially improving the clinical therapeutic outcome of hBMSC-based bone regeneration.

Abbreviations
AD: Adipocytic differentiation; ALP: Alkaline phosphatase; AUC: Area under the curve; BMI: Body mass index; BRL: Rosiglitazone; BSP: Bone sialoprotein; CFU-f: Colony-forming unit-fibroblast; COL1A: Collagen 1; DMEM: Dulbecco’s modified Eagle’s medium; EDTA: Ethylenediaminetetraacetic acid; FBS: Fetal bovine serum; hBMSCs: Human bone marrow stromal cells; IBMX: 3-Isobutyl-1-methylxanthine; MEM: Minimum essential medium; OB: Osteoblastic cells; OCN: Osteocalcin; PBS: Phosphate-buffered saline; PDGFRα: Platelet-derived growth factor receptor α; PDPN: Podoplanin; PDT: Population doubling time; PFA: Paraformaldehyde; P/S: Penicillin/streptomycin; qRT-PCR: Quantitative real-time PCR

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13287-021-02338-1.

Additional file 1: Supplementary Figure 1. Comparison of osteoblastic differentiation outcome measures at day 14 of osteoblastic differentiation. Graphs illustrate the different parameters which in addition to (A) alizarin red could serve as osteoblastic differentiation outcome measures, including (B) BSP gene expression, (C) COL1A gene expression, (D) OCN gene expression. The values shown are analyzed
Acknowledgements
The study was carried out as a part of BONEBANK project (project number: 16-1.0-15), supported by Interreg 5a Germany-Denmark, the European Regional Development, The NovoNordisk Foundation NNF (180C0054118), and the Lundbeck foundation (R266-2017-2450).

Authors’ contributions
JMK: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. The author(s) read and approved the final manuscript.

Funding
Interreg European Regional Development (16-1.0-15), The NovoNordisk Foundation NNF (180C0054118), Lundbeck foundation (R266-2017-2450).

Availability of data and materials
The data that support the findings of this study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Declarations
Ethics approval and consent to participate
The project was approved by the Scientific Ethical Committee of region of Southern Denmark (project ID: S-20160084). All subjects received oral and written information and signed a consent form.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interest.

Author details
1Department of Endocrinology, Odense University Hospital, Odense, Denmark. 2Department of Clinical Immunology, Odense University Hospital, Odense, Denmark. 3Molecular Endocrinology Unit (KMEB), Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. 4OPEN - Open Patient data Explorative Network, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 5Department of Clinical Immunology, Odense University Hospital, Odense, Denmark. 6Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 7Department of Orthopedics and Traumatology, Odense University Hospital, Odense, Denmark. 8Department of Orthopedics and Trauma Surgery, Medical Center - Albert-Ludwigs-University of Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany. 9Department of Cellular and Molecular Medicine, Danish Stem Cell Center (DanStem), University of Copenhagen, 2200 Copenhagen, Denmark.

Received: 26 October 2020 Accepted: 19 April 2021
Published online: 03 May 2021

References
1. Zaher W, Harkness L, Jafari A, Kassem M. An update of human mesenchymal stem cell biology and their clinical uses. Arch Toxicol. 2014;88(5):1069–82. https://doi.org/10.1007/s00204-014-1232-8.
2. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829–48. https://doi.org/10.3727/096368916X750552.
3. O’Keefe RJ, Tuin RS, Lane NE, et al. American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies. J Bone Miner Res. 2019;35(3):1–17.
4. Rauch A, Haakonsson AK, Madsen JGS, Larsen M, Foss I, Madsen MR, et al. Osteogenesis depends on commissioning of a network of stem cell transcription factors that act as repressors of adipogenesis. Nat Genet. 2019;51(4):716–27. https://doi.org/10.1038/s41588-019-0359-1.
5. Abdallah BM, Ditzel N, Kassem M. Assessment of bone formation capacity using in vivo transplantation assays: procedure and tissue analysis. Methods Mol Biol. 2008;455:89–100. https://doi.org/10.1007/978-1-59745-104-8_6.
6. Kristensen LP, Chen L, Nielsen MO, Qanie DW, Kratchmarova I, Kassem M, et al. Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells. Mol Cell Proteomics. 2012;11(10):1089–1107. https://doi.org/10.1074/mcp.M111.012138.
7. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33. https://doi.org/10.1016/j.stem.2018.05.004.
8. Luk F, de Witte SF, Korevaar SS, et al. Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells Dev. 2016;25(18):1342–54. https://doi.org/10.1089/scd.2016.0068.

9. Maracci M, Kon E, Moukhachev V, Lavrovuk A, Kutepov S, Quarto R, et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng. 2007;13(5):947–55. https://doi.org/10.1089/ten.2006.0271.

10. Giannotti S, Trombi L, Bottai V, Ghilardi D, Alesandrini D, Santi S, et al. Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessment. PLoS One. 2013;8(8):e73893. https://doi.org/10.1371/journal.pone.0073893.

11. Quarto R, Mastrogiacomo M, Cancicza D, Kutepov SM, Kutepov SM, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 2001;344(5):385–6. https://doi.org/10.1056/NEJM200102013440516.

12. Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, et al. Stem cell-based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study. Mol Ther. 2013;21(8):1631–8. https://doi.org/10.1038/mt.2013.109.

13. Orany A, Kamali A, Mohshir A, Baghaban Eslaminejad M. Role of mesenchymal stem cells in bone regenerative medicine: what is the evidence? Cells Tissues Organs. 2017;204(2):59–83. https://doi.org/10.1159/000469704.

14. FDA. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use, evidence? Cells Tissues Organs. 2017;204(2):59–83. https://doi.org/10.1159/000469704.

15. Oryan A, Kamali A, Baghaban Eslaminejad M. Role of mesenchymal stem cells in bone regenerative medicine: what is the evidence? Cells Tissues Organs. 2017;204(2):59–83. https://doi.org/10.1159/000469704.

16. Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 2001;344(5):385–6. https://doi.org/10.1056/NEJM200102013440516.

17. Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 2001;344(5):385–6. https://doi.org/10.1056/NEJM200102013440516.

18. FDA. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use, evidence? Cells Tissues Organs. 2017;204(2):59–83. https://doi.org/10.1159/000469704.

19. Oryan A, Kamali A, Mohshir A, Baghaban Eslaminejad M. Role of mesenchymal stem cells in bone regenerative medicine: what is the evidence? Cells Tissues Organs. 2017;204(2):59–83. https://doi.org/10.1159/000469704.
human marrow stromal cell cultures. Calcif Tissue Int. 2002;71(1):36–44. 
https://doi.org/10.1007/s00223-001-2059-x.

47. Stenderup K, Rosada C, Justesen J, al-Soubby T, Dagnaes-Hansen F, Kassem M. Aged human bone marrow stromal cells maintaining bone forming capacity in vivo evaluated using an improved method of visualization. Biogerontology. 2004;5(2):107–18. https://doi.org/10.1023/B:BGEN.0000025074.88476.e2.

48. Yoshikawa T, Ohgushi H, Ichiyama K, Takakura Y. Bone regeneration by grafting of cultured human bone. Tissue Eng. 2004;10(5-6):688–98. https://doi.org/10.1089/ten.2004.10.688.

49. Etghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S. Rejuvenation of osteoblastogenesis by the combination of 25(OH)D3 and parathyroid hormone in MSCs from elders. J Steroid Biochem Mol Biol. 2014;151:14–22. https://doi.org/10.1016/j.jsbmb.2012.09.002.

50. Hess R, Pino AM, Rios S, et al. High affinity leptin receptors are present in osteoblast-lineage cells in humans. N Engl J Med. 2005;352(19):1959–66. https://doi.org/10.1056/NEJMoa044264.

51. Tencerova M, Frost M, Figgec F, Nielsen TK, All D, Lauterlein JJL, et al. Obesity-associated hypermetabolism and accelerated senescence of bone marrow stromal stem cells suggest a potential mechanism for bone fragility. Cell Rep. 2019;27(7):2050–62 e2056. https://doi.org/10.1016/j.celrep.2019.04.066.

52. Corrigan MA, Coyle S, Eichholz KF, et al. Aged osteoporotic bone marrow stromal cells demonstrate defective recruitment, mechanosensitivity, and matrix deposition. Cells Tissues Organs. 2011;1–14.

53. Hess R, Pino AM, Rios S, et al. High affinity leptin receptors are present in human mesenchymal stem cells (MSC) derived from control and osteoporotic donors. J Cell Biochem. 2005;94(1):50–7. https://doi.org/10.1002/jcb.20330.

54. Rodriguez JP, Gonzalez M, Rios S, et al. Cytoskeletal organization of human mesenchymal stem cells (MSC) changes during their osteogenic differentiation. J Cell Biochem. 2004;93(4):721–31. https://doi.org/10.1002/jcb.20234.

55. Lou YR, Toh TC, Tee YH, Yu H. 25-Hydroxyvitamin D3 induces osteogenic alkaline phosphatase expression. Stem Cells Dev. 2012;21(16):2958–66. https://doi.org/10.1089/scd.2011.0349.

56. Zhou S, Glowacki J, Kim SW, Hahne J, Geng S, Mueller SM, et al. Clinical characteristics influence in vitro action of 1,25-dihydroxyvitamin D3 in human marrow stromal cells. J Bone Miner Res. 2002;17(1):50–7. https://doi.org/10.1016/j.jbmr.1655.

57. Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S. Rejuvenation of osteoblastogenesis by the combination of 25(OH)D3 and parathyroid hormone in MSCs from elders. J Steroid Biochem Mol Biol. 2014;151:14–22. https://doi.org/10.1016/j.jsbmb.2012.09.002.

58. Zhou S, Leffoff MS, Glowacki J. Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology. 2010;151(1):14–22. https://doi.org/10.1210/en.2009-0969.

59. Zhou S, Glowacki J, Kim SW, Hahne J, Geng S, Mueller SM, et al. Clinical characteristics influence in vitro action of 1,25-dihydroxyvitamin D3 in human marrow stromal cells. J Bone Miner Res. 2002;17(9):1992–2000. https://doi.org/10.1002/jbmr.1655.

60. Liu J, Nam HK, Campbell C, Gasque KCS, Millan JL, Hatch NE. Tissue-nonspecific alkaline phosphatase deficiency causes abnormal craniofacial bone development in the Alpl(-/-) mouse model of infantile hypophosphatasia. Bone. 2014;67:81–94. https://doi.org/10.1016/j.bone.2014.06.040.

61. Sacchetti B, Funari A, Michienzi S, di Cesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinuses can organize a hematopoietic microenvironment. Cell. 2007;131(2):324–36. https://doi.org/10.1016/j.cell.2007.08.025.

62. Uezumi A, Fukada S, Yamamoto N, Ikiimoto-Uezumi M, Nakatani M, Morita M, et al. Identification and characterization of PDGFalpha+ mesenchymal progenitors in human skeletal muscle. Cell Death Dis. 2014;5(4):e1186. https://doi.org/10.1038/cddis.2014.161.

63. Samsonraj RM, Rai B, Sathiyanathan P, Puan KJ, Rötzschke O, Hui JH, et al. Establishing criteria for human mesenchymal stem cell potency. Stem Cells. 2015;33(6):1878–91. https://doi.org/10.1002/stem.1982.

64. Lin CS, Ning H, Lin G, Lue TF. Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy. 2012;14(10):1159–63. https://doi.org/10.3109/14653249.2012.729817.

65. Burns JS, Rasmussen PL, Larsen KH, Schrader HD, Kassem M. Parameters in three-dimensional osteospheroids of telomerized human mesenchymal (stromal) stem cells grown on osteoconductive scaffolds that predict in vivo bone-forming potential. Tissue Eng Part A. 2010;16(7):2331–42. https://doi.org/10.1089/ten.tea.2009.0735.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 1000000 website views per year

At BMC, research is always in progress.

Learn more biomedicalcentral.com/submissions